EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines : Anti-Cancer Drugs

Journal Logo

Case report

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines

Nowaczyk, Joannaa; Fret, Kamila; Kaminska-Winciorek, Grazynab; Rudnicka, Lidiaa; Czuwara, Joannaa

Author Information
Anti-Cancer Drugs ():10.1097/CAD.0000000000001494, January 24, 2023. | DOI: 10.1097/CAD.0000000000001494
  • Open
  • PAP

Abstract

Introduction

Epidermal growth factor receptor (EGFR) plays a crucial role in the pathways of cell division, apoptosis, and epithelial differentiation [1]. This receptor became a therapeutic target in oncology when a connection between its overexpression and processes of proliferation, angiogenesis, and metastasis in cancers has been found [1]. Three types of anticancer therapeutics inhibiting EGFR are used in clinical practice – monoclonal antibodies (such as cetuximab and panitumumab), tyrosine kinase inhibitors (such as gefitinib, erlotinib), or multispecific tyrosine kinase such as EGFR/HER2 inhibitors (afatinib, neratinib, and lapatinib). The latter acts against EGFR tyrosine kinase and also against vascular endothelial growth factor receptor (VEGFR) and rearranged during transfection (RET) signaling. Among solid tumors that may be qualified for this therapy are those originating from the epithelial tissue, for example, non-small cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma (HNSCC), and breast cancer [1].

EGFR is found not only in epidermal cells but also in other dermal structures [1]. This may explain the presence of dose-dependent dermatological side effects of anti-EGFR therapy [1,2], which may affect the patient’s quality of life [3]. Most common adverse events are acneiform papulopustular rash (affecting 30–80% of patients), xerosis (20–50%), and paronychia (3–30%) [1] (Fig. 1). Hair conditions appear as late-side effects, affecting 1–5% of patients [1]. A very rare complication is folliculitis decalvans, a type of neutrophilic cicatricial alopecia most commonly occupying the vertex of the scalp [4]. If left untreated, this disease may cause progressive and irreversible hair loss due to hair follicle destruction.

F1
Fig. 1:
Common cutaneous adverse reactions of EGFR inhibitors. EGFR, epidermal growth factor receptor.

Case series

We included a consecutive series of three patients who were diagnosed and treated for folliculitis decalvans while on afatinib therapy from 2019 to 2020 in two dermatologic reference centers in Poland.

Case I

A 65-year-old Caucasian woman presented to the dermatological clinic due to scalp pruritus, rigid hair, and moderate hair loss. She had been taking afatinib for lung adenocarcinoma for 5 months. The woman also experienced facial erythema, nummular dermatitis, paronychia, and hyperkeratosis of her palms and soles. Treatment for hair loss was not recommended at that point, while adequate treatment was applied for the remaining conditions. Four months later, the woman returned with progressive alopecia with yellow crusting on the vertex, which started over two months earlier (Fig. 2a). Moreover, pyogenic granuloma of the index finger and inflammation of palms and soles were observed. Trichoscopy findings of the scalp included diffuse erythema, thin arborizing vessels, pili torti, yellow crusts, and purulent discharge (Fig. 3a). Based on these characteristic findings, folliculitis decalvans was diagnosed.

F2
Fig. 2:
Macroscopic image of the first (a), second (b and c), and third patient (d). (a) Yellow crusts, extravasations, erythema, and alopecia on the vertex of the scalp (first patient). (b) Pili torti and atrichous areas on the frontal area (second patient). (c) Tufted hair and alopecia on the parieto-occipital area (second patient). (d) Yellow crusts, extravasations, erythema, and alopecia on the vertex of the scalp (third patient).
F3
Fig. 3:
Trichoscopy of the first (a), second (b and c), and third patient (d). (a) Yellow crusts, whitish purulent discharge, extravasations, and pili torti (first patient). (b) Erythematous base and pili torti (second patient). (c) Hair tufts with polytrichia, tubular scaling formation, and crusts (second patient). (d) Hair tufts with polytrichia, erythematous base, and follicular pustules (third patient).

The patient received tetracycline (500 mg twice daily) and topical hydrocortisone butyrate. Improvement was observed after 2 months and the dosage of tetracycline was reduced to 250 mg twice daily.

Case II

A 43-year-old Caucasian woman was referred to the dermatology clinic due to 1-month history of progressive folliculitis of her scalp. The patient had been undergoing treatment with afatinib (30 mg per day) for NSCLC. Physical examination of the scalp revealed hair loss, erythema, as well as tufted and twisted hairs on the frontal and parieto-occipital regions (Fig. 2b and c). Moreover, the patient experienced paronychia and acneiform papulopustular facial rash. Prior to the dermatology admission, the scalp lesions were treated with doxycycline and ciprofloxacin without improvement. Trichoscopic examination of the scalp revealed hair tufts, polytrichia, pili torti, crusts, scales, and blood extravasation (Fig. 3b and c). On this basis, folliculitis devalvans was diagnosed.

Initially, the scalp lesions were unsuccessfully treated with tetracycline (500 mg twice daily, then 750 mg twice daily) for one month. Improvement was finally achieved after 1-month of therapy with doxycycline (100 mg twice daily) combined with topical clobetasol propionate and hydrocortisone butyrate. After 2 months after the first appointment, neither scales nor crusts were present in trichoscopy; however, some purulent discharge was persistent. Therefore, maintenance therapy with doxycycline (100 mg once daily), topical hydrocortisone butyrate, and topical mupirocin was introduced.

Case III

A 38-year-old Caucasian woman was consulted by a dermatologist due to 1-month history of severe pustular lesions located on her scalp, accompanied by pruritus and partial hair loss. For the last 24 months, the patient had been treated with afatinib for lung adenocarcinoma. Due to pneumonia, since the 15th week of the afatinib therapy, the woman had been treated at the altered dose of 20 mg once a day. In physical examination of the scalp, erythema and yellow crusts were observed on the vertex (Fig. 2d). In trichoscopy, the lesions had an appearance of perifollicular pustules with a tendency to form purulent and dried scabs (Fig. 3d). In microbiological examination of the scalp swab, methicillin-sensitive Staphylococcus aureus was cultured, with a sensitivity for doxycycline, fusidic acid, and amoxycillin with clavulanic acid. On the basis of these findings, folliculitis devalvans was diagnosed.

Doxycycline was administered at a dose of 100 mg twice daily for 5 days, followed by 100 mg daily, and then tapered to 50 mg four times a day for the next 20 days owing to gastric symptoms. Additionally, mupirocin and betamethasone valerate with fusidic acid was prescribed topically. An improvement was noted 35 days later, with a total resolution of pustules and scaling (Fig. 4a and b).

F4
Fig. 4:
Clinical and trichoscopic improvement of the third patient. (a) Complete resolution of the scalp lesions (compare to Fig. 2d). (b) Trichoscopic findings characteristic for folliculitis decalvans are not present (compare to Fig. 3d).

Discussion

To the best of our knowledge, this is the first case series of patients who developed folliculitis decalvans during afatinib therapy. Our three patients join the group of a few described cases of folliculitis decalvans during anti-EGFR therapy, as summarised in Table 1, [2,5–11]. In the literature reported cases of folliculitis decalvans, the median time from the start of EGFR inhibitors to the first symptoms of alopecia was 4 months (range: 1–23 months). The hair loss was often preceded by a rash, which was usually the first observed adverse reaction [5,7,9,10]. The hair loss was often followed by palmoplantar dermatitis [6], paronychia [10], and pyogenic granuloma [6] appearing weeks later.

Table 1 - Literature review of other case reports describing folliculitis decalvans as an adverse event of epidermal growth factor receptor inhibitors
Study Age, sex Cancer type EGFRI Dosage of EGFRI S. aureus scalp infection Final treatment of folliculitis decalvans Improvement of folliculitis decalvans (time)
Anzengruber et al. 51 M HNSCC Cetuximab 500 mg per day Yes Topical corticosteroids (class III), antiseptics Yes (after 3 weeks)
Dervout et al. 54 F Pulmonary adenocarcinoma Erlotinib no data No data Amoxicillin+clavulanic acid, topical corticosteroids, EGFR inhibitor discontinuation Yes
Ena et al. 56 F Breast cancer Lapatinib 1250 mg per day No EGFR inhibitor dose reduction (to 1000 mg per day) yes
Hoekzema et al. 60 F Metastatic NSCLC Erlotinib 150 mg per day Yes (MSSA) Minocycline (100 mg per day), desoximetasone 0.25% emulsion (once daily); maintenance: minocycline (50 mg per day for 2 months) Yes (within 3 weeks)
Keith et al. 76 M Metastatic pulmonary adenocarcinoma Erlotinib no data, mainten-ance dose of 75 mg per day No data Oxytetracycline (500 mg twice daily), betamethasone 0.1% with clioquinol 3% cream, cetrimide 10% with undecanoic acid 1% shampoo Yes
Rosman et al. 47 F Breast cancer Trastuzumab No data No data Topical clobetasol propionate 0.05% (twice a day) Yes (‘quick’)
Sahuquillo-Torralba et al. 66 M Metastatic pulmonary adenocarcinoma Erlotinib 150 mg per day Yes (MSSA) EGFRI dose reduction (to 100 mg per day), doxycycline (100 mg twice a day) No
Shih et al. 72 F NSCLC Gefitinib 250 mg per day Yes Fluocinonide cream, fusidic acid, doxycycline (1 month) No (improvement when EGFRI stopped)
Ficlatuzumab 20 mg/kg every 2 weeks
73 F NSCLC Gefitinib 250 mg per day Yes Fluocinonide, desoximetasone ointment, fusidic acid cream, doxycycline (200 mg per day for 4 months), cephalexin (2 g per day for 1 month) No
Ficlatuzumab 20 mg/kg every 2 weeks
EGFRI, EGFR inhibitor; F, female; HNSCC, head and neck squamous cell carcinoma; M, male; NSCLC, non-small cell lung carcinoma; S. aureus, Staphylococcus aureus.

Pathogenesis

Cutaneous toxicity of EGFR inhibitors originates from the interfered processes of proper maturation and differentiation of keratinocytes, mostly in the seborrheic areas of the skin [1,12,13]. Furthermore, the chemoattractant activity of EGFR inhibitors causes neutrophil chemotaxis and leads to sterile folliculitis [4,12]. A subsequent bacterial superinfection often co-occurs as EGFR inhibitors impair the antimicrobial defense of the skin [12,13]. In patients previously treated with radiation therapy, EGFR inhibitor-induced acne-like rash was found to spare the previously irradiated body regions due to radiation-induced follicular loss [14–16].

Diagnostic process

Quick diagnostic process is an important first step in management of folliculitis decalvans, as this condition may lead to progressive scarring and permanent hair follicle loss which meaningly affect the patient’s quality of life. Pain, itching, and burning associated with the disease also play a significant role in patient’s wellbeing [4]. However, itching and hair casts can also appear as a result of stress accompanying anticancer therapy and may not be associated with folliculitis decalvans [6].

In favor of noninvasiveness, simplicity of implementation, and widespread availability, the main diagnostic tool of folliculitis decalvans is a dermatoscope to perform trichoscopy. Trichoscopy is a diagnostic examination of the scalp surface, visualized at magnification and usually in polarised light. Characteristic signs of folliculitis decalvans in trichoscopy consist of hair tufts, yellow purulent discharge, perifollicular erythema, follicular hyperkeratosis, extravasations, pili torti, dystrophic hair, broken hair, and atrichous areas [4,17–20]. The term hair tufts concerns polytrichia, when 5–20 hairs become grouped into doll’s hair-like follicular bundles, as a result of grouping the destructed outer root sheaths of follicles by the neutrophil-rich inflammatory infiltrate to non-inflammatory areas [4,21,22].

If the trichoscopic examination fails to confirm a diagnosis, a punch biopsy taken from the pustular or papular lesions should be considered; however, this is not routinely required. Histopathological features indicating folliculitis decalvans are intrafollicular and perifollicular inflammatory infiltrates rich in neutrophils and plasma cells. Pustules form around the upper portion of the affected follicles. Epithelia of the follicles are hypertrophic with marked neutrophils exocytosis. With time, epithelia become destructed leading to naked hair shafts release and foreign body granulomas formation followed by fibrosis after resolution [2,5–9].

Bacterial superantigens of S. aureus may also be involved in the etiopathogenesis of folliculitis decalvans [4,23]. S. aureus is almost always obtained from microbiological culture of material collected from the lesions [4–7,9,10]. Treatment of superinfection is important to prevent the development of bacteriaemia and sepsis in immunocompromised patients [13].

Management

Despite that typical and EGFR inhibitor-induced folliculitis decalvans have different backgrounds, for both types of the disease, a similar therapeutic approach with antimicrobial and immunomodulating medications can be applied.

Treatment of EGFR inhibitor-induced folliculitis decalvans frequently consists of oral tetracycline, topical steroids, and optional topical antibiotics (Table 2). Oral tetracyclines, especially doxycycline, are recommended in the treatment of folliculitis decalvans [4,24] due to their anti-inflammatory and antibacterial properties. Tetracyclines were also used in management of our patients and most of the literature-reported cases of folliculitis decalvans (Table 1). Therapeutic options for treatment induction include either doxycycline 100–200 mg twice daily, tetracycline 500–1000 mg twice daily, or minocycline 100 mg twice daily [25]. Therapy duration with tetracyclines should be continued for 4 up to 16 weeks; however, it may be prolonged to a few months or even years if the course of disease is recalcitrant or relapsing [25]. After marked improvement, medication can be tapered from the initially maximal, antibacterial doses to usually a half lower, anti-inflammatory doses for remission maintenance. Both EGFR inhibitors and tetracyclines require protection from UV radiation, therefore, patients must avoid sun exposure or use appropriate photoprotection (sun creams with sun protection factor, and clothing covering the skin) [26]. Treatment with tetracyclines is usually well-tolerated, although high doses may contribute to gastrointestinal upset or diarrhea, especially in regard to minocycline [27].

Table 2 - Proposed management of anti-epidermal growth factor receptor inhibitor-induced folliculitis decalvans
Route Group First-line Second-line
Oral Doxycyline 100–200 mg twice daily Rifampicin 150–300 mg twice daily with clindamycin 300 mg twice daily or daily.
Antibiotics p.o. Tetracycline 500–1000 mg twice daily Isotretinoin 0.1–1.0 mg/kg/d or 30 mg/day
Minocycline 100 mg twice daily Dapsone 100 mg/day
AND
Topical Hydrocortisone butyrate
Corticosteroids top. Clobetasol propionate
Betamethasone valerate
OR
Fusidic acid
Antibiotics top. Mupirocin
Erythromycin
Intra-lesional OR
Corticosteroids s.c. Triamcinolone

Other systemic medications that show efficacy involve rifampicin (150–300 mg twice daily) with clindamycin (300 mg twice daily or daily), isotretinoin (0.1–1.0 mg/kg/day or 30 mg/day), and dapsone (100 mg/day) [4,24].

Topical antibiotics (such as fusidic acid, mupirocin, erythromycin) [4] and topical steroids (such as hydrocortisone butyrate, clobetasol propionate, and betamethasone valerate) [2,5] or intralesional triamcinolone [24,25] can be used adjuvantly to increase the efficacy of the treatment, but only in combination with the systemic therapy [7,8]. Topical steroids were applied in all three of our cases and additionally, in two of our cases (including the one with S. aureus detected) topical antibiotics were prescribed. Topical medications were also commonly used in the management of other literature-reported cases of folliculitis decalvans (Table 1).

Furthermore, patients should be advised to use gentle hair products and avoid harsh anti-dandruff shampoos, hot-air blow drying, and aggressive hair styling [26].

Prevention

Recently, a proactive (preventive) approach to cutaneous toxicities of EGFR inhibitors has been studied to improve the patients’ quality of life, maintain treatment compliance, and avoid dose changes or interruptions of anti-EGFR therapy [28–30]. Pre-emptive use of low-dose systemic or topical tetracyclines [28,31,32] with topical steroids [29,33] for EGFR inhibitor-induced cutaneous adverse events have been analyzed in randomized open-label trials and a retrospective cohort study showing promising outcomes in reducing the incidence or severity of a rash but not necessarily other side effects, including hair disorders.

Decision upon epidermal growth factor receptor-inhibitor dose reduction

One of the challenges in management of folliculitis decalvans is the resistance to the therapy [4] or disease recurrence. Ineffective treatment of severe or progressive folliculitis decalvans may require a dose reduction [6,10] or in critical cases even a discontinuation of the anti-cancer drug until improvement is required [11]. This decision should be made cautiously and primarily the control of the underlying oncological disease should be considered [9]. Some patients may also decide to abruptly stop the anti-EGFR therapy owing to severe cutaneous adverse events causing pain, itching, and cosmetic concerns. Therefore, it is important for the oncologists to inform the patient beforehand about these manageable side effects and refer to a dermatologist at early stage instead of in the case of persistence or worsening of the skin lesions [34].

Acknowledgements

J.C. and G.K.W. provided clinical data. J.N. and K.F. analyzed the data and drafted the article. All authors participated in the discussion and revised the article.

Patients have given consent for publication.

Conflicts of interest

There are no conflicts of interest.

References

1. Saraswat N, Sood A, Kumar D, Verma R, Sushil K. Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: a prospective observational study of 76 cases. Indian Dermatol Online J 2019; 10:251–255.
2. Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010; 5:295–296.
3. Osio A, Mateus C, Soria J-C, Massard C, Malka D, Boige V, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161:515–521.
4. Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther 2008; 21:238–244.
5. Anzengruber F, Meier B, Maul JT, Kerl K, French LE, Navarini AA. Extreme phenotype of epidermal growth factor receptor inhibitor-induced destructive folliculitis. Int J Trichol 2016; 8:176–179.
6. Ena P, Fadda GM, Ena L, Farris A, Santeufemia DA. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer. Clin Exp Dermatol 2008; 33:790–791.
7. Hoekzema R, Drillenburg P. Folliculitis decalvans associated with erlotinib. Clin Exp Dermatol 2010; 35:916–918.
8. Keith DJ, Stewart DG. Erlotinib-induced folliculitis decalvans. Clin Exp Dermatol 2013; 38:924–925.
9. Sahuquillo-Torralba A, Escutia-Muñoz B, Rodríguez-Serna M, Botella-Estrada R. Folliculitis decalvans caused by bacterial superinfection secondary to erlotinib. Actas Dermo-Sifiliográficas (English Edition) 2018; 109:363–364.
10. Shih YH, Chen PC, Chu CY. Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib. J Clin Oncol 2013; 31:e335–e337.
11. Dervout C, Chiappa A-M, Fleuret C, Plantin P, Acquitter M. Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation. Ann Dermatol Venereol 2020; 147:848–852.
12. Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, et al. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash. J Dermatol 2020; 47:121–127.
13. Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer 2016; 24:3943–3950.
14. Eguren C, Domínguez-Fernández I, Santiago-Sánchez-Mateos DI, García-Díez A. Erlotinib-induced acneiform rash not affecting previously irradiated skin. Actas Dermosifiliogr 2010; 101:186–187.
15. Yalçin S, Dizdar O, Yalçin B, Gököz O. Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol 2008; 58:178–179.
16. Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 2007; 18:601–602.
17. Saceda-Corralo D, Moreno-Arrones OM, Rodrigues-Barata R, Rubio-Lombraña M, Mir-Bonafé JF, Morales-Raya C, et al. Trichoscopy activity scale for folliculitis decalvans. J Eur Acad Dermatol Venereol 2020; 34:e55–e57.
18. Rudnicka L, Olszewska M, Rakowska A, Slowinska M. Trichoscopy update 2011. J Dermatol Case Rep 2011; 5:82–88.
19. Rakowska A, Slowinska M, Kowalska-Oledzka E, Warszawik O, Czuwara J, Olszewska M, et al. Trichoscopy of cicatricial alopecia. J Drugs Dermatol 2012; 11:753–758.
20. Hoffmann A, Waśkiel-Burnat A, Żółkiewicz J, Blicharz L, Rakowska A, Goldust M, et al. Pili Torti: a feature of numerous congenital and acquired conditions. J Clin Med 2021; 10:3901.
21. Baroni A, Romano F. Tufted hair folliculitis in a patient affected by pachydermoperiostosis: case report and videodermoscopic features. Skinmed 2011; 9:186–188.
22. Tarantino I, Fischer R, Rajpara A. Tufts of ‘doll’s hair’ within a shiny, scarring alopecia. J Am Acad Dermatol 2016; 74:e109–e110.
23. Vañó-Galván S, Molina-Ruiz AM, Fernández-Crehuet P, Rodrigues-Barata AR, Arias-Santiago S, Serrano-Falcón C, et al. Folliculitis decalvans: a multicentre review of 82 patients. J Eur Acad Dermatol Venereol 2015; 29:1750–1757.
24. Rambhia PH, Conic RRZ, Murad A, Atanaskova-Mesinkovska N, Piliang M, Bergfeld W. Updates in therapeutics for folliculitis decalvans: a systematic review with evidence-based analysis. J Am Acad Dermatol 2019; 80:794–801.e1.
25. Bunagan MJK, Banka N, Shapiro J. Retrospective review of folliculitis decalvans in 23 patients with course and treatment analysis of long-standing cases. J Cutan Med Surg 2015; 19:45–49.
26. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, Luger T, Triller R, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol 2013; 27:1071–1080.
27. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133:1224–1230.
28. Deplanque G, Gervais R, Vergnenegre A, Falchero L, Souquet P-J, Chavaillon J-M, et al. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial. J Am Acad Dermatol 2016; 74:1077–1085.
29. Yu Z, Bach DQ, LeBoeuf NR. Use of preemptive treatment for epidermal growth factor receptor inhibitor-related skin toxicity: The Dana Farber Cancer Institute experience. J Am Acad Dermatol 2020; 83:AB35.
30. Hofheinz R-D, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, et al. Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 2016; 21:1483–1491.
31. Arrieta O, Vega-González MT, López-Macías D, Martínez-Hernández JN, Bacon-Fonseca L, Macedo-Pérez EO, et al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. Lung Cancer 2015; 88:282–288.
32. Shacham Shmueli E, Geva R, Yarom N, Hubert A, Keynan R, Kedem TH, et al. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. Support Care Cancer 2019; 27:3027–3033.
33. Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, et al. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Support Care Cancer 2021; 29:2327–2334.
34. Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, André T, Bensadoun RJ, et al. Regional expert groups PROCUR. Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians. J Eur Acad Dermatol Venereol 2013; 27:419–429.
Keywords:

adverse events; afatinib; case series; epidermal growth factor receptor-inhibitor; folliculitis decalvans; management guidelines; skin toxicity

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.